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Abstract
Breast cancer is one of the most important causes of cancer-related deaths worldwide in
women. In addition to gene expression studies, the progressing work in the miRNA area
including miRNA microarray studies, brings new aspects to the research on the cancer de-
velopment and progression. Microarray technology has been widely used to find new bio-
markers in research and many transcriptomic microarray studies are available in public
databases. In this study, the breast cancer miRNA and mRNAmicroarray studies were col-
lected according to the availability of their data and clinical information, and combined by a
newly developed ranking-based meta-analysis approach to find out candidate miRNA bio-
markers (meta-miRNAs) that classify breast cancers according to their grades and explain
the relation between miRNAs and mRNAs. This approach provided meta-miRNAs specific
to breast cancer grades, pointing out let-7 family members as grade classifiers. The qRT-
PCR studies performed with independent breast tumors confirmed the potential biomarker
role of let-7 family members (meta-miRNAs). The concordance between the meta-mRNAs
and miRNA target genes specific to tumor grade (common genes) supported the idea of
mRNAs as miRNA targets. The pathway analysis results showed that most of the let-7 fami-
ly miRNA targets, and also common genes, were significantly taking part in cancer-related
pathways. The qRT-PCR studies, together with bioinformatic analyses, confirmed the re-
sults of meta-analysis approach, which is dynamic and allows combining datasets from
different platforms.
Introduction
Breast cancer (BC) is the second leading cause of cancer-related deaths worldwide in women,
after lung cancer. Despite advances in early detection and treatment, the estimated number of
deaths in 2014 due to BC is about 40,000. The chance of a woman having invasive breast cancer
during her lifetime is about 1 in 8. The chance of dying from breast cancer is about 1 in 36 [1].
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BC is a complex and heterogeneous disease with varied molecular features, tumor characteris-
tics, expression patterns and response to therapy. It has been studied in detail at the molecular
level. Although some genes were found to be responsible for the development and progression
of the disease, most of the molecular mechanisms underlying its progression remain poorly un-
derstood. This has led to a significant interest in the quest for novel predictive markers for BC
[2,3].
The clinical management of breast cancer depends on the availability of robust clinical and
pathological prognostic factors. One of the best-established prognostic factors for BC is histo-
logical grade, which is based on the degree of differentiation of the tumor tissue. Recent micro-
array-based expression profiling studies have provided evidence that tumors of different grades
show distinct genomic, transcriptomic and immunohistochemical profiles [4].
MicroRNAs (miRNAs) are small non-coding RNA molecules, which negatively regulate
gene expression at the post-transcriptional level [5]. Following the discovery of the first
miRNA in the roundworm Caenorhabditis elegans, these short regulatory RNAs have been
found to be an abundant class of RNAs in plants, animals, and DNA viruses. miRNAs induce
mRNA degradation (some studies indicate that destabilization of target mRNAs is the predom-
inant reason for reduced protein output), translational repression, or both depending upon the
complementarity of the miRNA to its mRNA target [6–8]. miRNAs play a crucial role in nor-
mal biological processes including development, cell proliferation, differentiation, and apopto-
sis [9]. Future work on miRNAs and miRNA microarray studies will elucidate new areas of
cancer development and progression. Intensifying research in miRNA studies, using high
throughput techniques including microarrays has resulted in the identification and confirma-
tion of aberrant miRNA expression in a number of human diseases including BC [3,5].
The let-7 family of miRNAs was initially discovered as important developmental molecules
in C. elegans. It is known that mature let-7 family members are highly conserved across animal
species and that these miRNAs are key regulators of cell proliferation and differentiation. Let-7
family members are often reported as tumor suppressors in humans. Altered let-7 family ex-
pression is likely to contribute to cancer formation and also progression. Accordingly, these
miRNAs may have the potential to be used as novel predictive markers in cancer [10,11].
Microarray technology has been widely used in research to find new biomarkers in the past
decade. Many transcriptomic microarrays have been generated and made available in public
databases such as the Gene Expression Omnibus (GEO)[12] from NCBI (http://www.ncbi.nlm.
nih.gov/geo/) and Array Express[13] from EBI (http://www.ebi.ac.uk/arrayexpress/) [14,15].
Meta-analysis may briefly defined as combining independent studies using various methods
to increase the statistical power by increasing the number of samples analyzed [16,17]. Meta-
analysis approaches have the potential to enable more comprehensive evaluation of the existing
differential miRNA expression data and can therefore provide miRNA and miRNA-target gene
sets with a high diagnostic value. In addition to ongoing discovery of new miRNAs and incon-
sistent annotation, platform variability, various methods for data processing, and analysis are
the limitations for combining independent datasets [17].
To overcome these limitations, we developed a ranking-based meta-analysis approach. It is
known that ranking-based meta-analysis approaches are successful in eliminating the differ-
ences that originate from platform variability [18]. The method enabled us to combine three in-
dependent miRNA microarray studies performed with three different platforms and two
different mRNA microarray studies performed with the same platform. Herein we provide
miRNA and mRNA lists that are discriminative specifically for breast cancer grades, which are
invariably expressed across independent experiments. In the miRNA list, eight of the let-7 fam-
ily members were found to be top-ranking miRNAs with a discriminative power for breast can-
cer grades and were validated by qRT-PCR. Consequently to the best of our knowledge this is
Meta-MicroRNAs in Breast Cancer
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the first meta-analysis study that combines and correlates miRNA and mRNA microarray
studies conducted in breast cancer.
Material and Methods
We explained the relation between miRNAs and mRNAs in addition to the identification of
miRNA signatures in this study. Accordingly the study steps were designed for both miRNA
and mRNA together (Fig 1).
Selection and restructuring of datasets
miRNA and mRNA microarray studies related to breast tumors were searched in two microar-
ray databases, Gene Expression Omnibus [12] (GEO, www.ncbi.nlm.nih.gov/geo/) and
ArrayExpress [13] (www.ebi.ac.uk/arrayexpress) using the search terms “miRNA” or “mRNA”,
“microarray” and “breast cancer” together. With these keywords we found 96 studies in which
52 of the microarray studies were performed with cell lines and 4 of them were formalin-fixed,
paraffin-embedded (FFPE) studies. The datasets that were generated by using cell lines and
FFPE tissue samples were excluded. The rest of the datasets were evaluated according to the
presence of their data and grade information. Only studies with miRNA and mRNA microar-
ray expression data conducted in human breast cancer tissues that had clinical information re-
garding grade status were included for further analysis.
Three miRNA datasets (GSE7842 [19], GSE15885 [20] and GSE22216 [21]) and 2 mRNA
datasets (GSE17907 [22] and E-MTAB-1006 [23]) were selected and downloaded as a “series
matrix” file and “processed data” file from GEO and ArrayExpress respectively. Each dataset
was then annotated and grade information files were restructured for standardization.
miRNA and mRNA datasets
Three breast cancer miRNA microarray studies and 2 breast cancer mRNAmicroarray studies
were retrieved from GEO and ArrayExpress (Table 1). All 5 datasets were taken from full-text
research articles published between 2007 and 2011.
Fig 1. General study andmeta-analysis scheme. The workflow is represented by boxes and arrows.
doi:10.1371/journal.pone.0126837.g001
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GSE7842 miRNA data from Blenkiron et al. [19] were generated using the Luminex Bead-
based microRNA profiling platform version 3. This dataset contained 93 primary human
breast tumors (20 samples were Grade 1, 34 samples Grade 2 and 39 samples Grade 3).
GSE15885 miRNA data from Lowery et al. [20] were generated using the Exiqon Homo sa-
piens 0.4K miChip v8. This dataset contained 29 early stage breast cancer specimens (5 samples
were Grade 1, 7 samples Grade 2 and 17 samples Grade 3).
The last miRNA data GSE22216 from Buffa et al. [21] were generated using the Illumina
Human v1 MicroRNA expression beadchip. This dataset contained 210 early primary breast
cancer samples (42 samples were Grade 1, 81 samples Grade 2, 63 samples Grade 3 and 24 of
an unknown grade).
GSE17907 [22] and E-MTAB-1006 [23] mRNA datasets were both generated using the
Affymetrix Human Genome U133 Plus 2.0 Array. GSE17907 contained 55 breast cancer sam-
ples (3 samples were Grade 1, 10 samples Grade 2, 34 samples Grade 3 and 8 of an unknown
grade) while E-MTAB-1006 contained 96 breast cancer samples (18 samples were Grade 1, 34
samples Grade 2 and 44 samples Grade 3).
The independent mRNAmicroarray test data GSE22219 from Buffa et al. [21] that was
used for in silico analysis were generated using the Illumina human Ref-8 v1.0 expression bead-
chip. This dataset contained 190 primary human breast tumors (41 samples were Grade 1, 87
samples Grade 2 and 62 samples Grade 3).
Meta-analysis
The limitations of meta-analysis of miRNA studies are inconsistent annotation, platform vari-
ability, various methods for data processing, and analysis resulting from the usage of different
platforms. To eliminate such limitations for combining independent datasets an ANOVA-de-
pendent ranking-based meta-analysis program was developed by using MATLAB. ANOVA
tests were performed to find the significance levels (p values) among samples with grade I, II
and III. For each study, the miRNA and mRNA lists were generated considering their p values,
and miRNAs and mRNAs were noted according to their ranks in the list. For each miRNA or
mRNA, the mean of its rank in all studies was calculated and this value became its real rank in
the meta-list, which was used instead of the significance value (Fig 1).
Pathway enrichment analysis
TheWebGestalt [24] (http://bioinfo.vanderbilt.edu/webgestalt/) pathway analysis tool was
used for enrichment analysis of the targets of the let-7 family members and the common targets
Table 1. The characteristics of the datasets used for meta-analysis.
miRNA studies Platform Grade 1 Grade 2 Grade 3
GSE7842 Luminex Bead-based microRNA profiling platform version 3 20 34 39
GSE15885 Exiqon Homo sapiens 0.4K miChip v8 5 7 17
GSE22216 Illumina Human v1 MicroRNA expression beadchip 42 81 63
Total 67 122 119
mRNA studies
E-MTAB-1006 Affymetrix Human Genome U133 Plus 2.0 Array 18 34 44
GSE17907 Affymetrix Human Genome U133 Plus 2.0 Array 3 10 34
Total 21 44 78
in silico test study
GSE22219 Illumina human Ref-8 v1.0 expression beadchip 41 87 62
doi:10.1371/journal.pone.0126837.t001
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of the meta-miRNAs and meta-mRNAs. The enrichment results of the let-7 family target genes
were visualized by a heatmap (Fig 2). The KEGG pathway enrichment results of the validated
target genes and FDR corrected p values were used as input for the Cluster 3.0 [25] and Tree-
View [26] programs.
Validation of meta-miRNAs by Real-Time quantitative RT-PCR
(qRT-PCR)
Breast tumor samples. Primary breast tumor samples were obtained from the patients during
the surgery, instantly snap-frozen in liquid nitrogen, and stored at -80°C until RNA extraction.
The total number of samples was 21. Four of the breast tumor samples were Grade 1, 11 were
Fig 2. Pathway enrichment of the grade-specific let-7 family targets. Validated targets of the let-7
miRNAs and KEGG pathway results were used to construct the heatmap. The intensity of color represents
the adjusted p value (p0.0091).
doi:10.1371/journal.pone.0126837.g002
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Grade 2 and 6 were Grade 3. This study and the use of the tissue material in this project were
approved by the Research Ethics Committee of Ankara University School of Medicine. The
written consent was obtained from the patients in accordance with the Helsinki Declaration.
RNA extraction and cDNA synthesis. The RNA isolation protocol was performed accord-
ing to the previous study [27]. Briefly, the frozen breast tumor samples were put into Trizol re-
agent (AppliChem, Darmstadt, Germany), disrupted with a homogenizer, and total RNA was
isolated according to the manufacturer’s instructions. Genomic DNA contamination was re-
moved by on-column DNase treatment (Macharel Nagel, Duren, Germany). The concentra-
tion of the isolated RNA and ratio of absorbance at 260 nm to 280 nm were measured with the
NanoDrop ND-1000 spectrophotometer (NanoDrop Technologies, Montchanin, DE, USA).
First-strand cDNA was synthesized from 1 μg total RNA with the miScript II RT Kit accord-
ing to the manufacturer’s instructions (Qiagen, Hilden, Germany). In a reverse-transcription
reaction, mature miRNAs were polyadenylated by poly(A) polymerase and subsequently con-
verted into cDNA by reverse transcriptase with oligo-dT priming. The cDNA was then used
for qRT-PCR profiling of mature miRNA expression. The cDNA was diluted at a ratio of 1:10
before being used as a PCR template and stored at -20°C until further use.
qRT-PCR. qRT-PCR analysis was performed on the Roche LightCycler 480 by using specif-
ic miRNA primers and the miScript SYBR Green PCR Kit (Qiagen, Hilden, Germany). The
amplification mixtures contained 1.0 μl 1:10 diluted cDNA, 5.0 μl SYBR Green PCRMaster
Mix, 1.0 μl miScript Universal Primer (reverse primer for all miRNAs), 1.0 μl miScript Primer
Assay (miRNA specific forward primer) and 2 μl RNase-free water in a total volume of 10 μl.
Cycling conditions were as follows: 95°C for 15 min for initial activation and then 40 cycles of
94°C for 15 s, 55°C for 30 s, and 70°C for 30 s during amplification. The ΔΔCt method was
used for the analysis of qRT-PCR results and RNU6-2 was used as a normalization factor.
Prediction of miRNA targets and their comparison with meta-mRNAs
The validated targets of the grade-specific meta-miRNAs were identified bioinformatically by
using miRWalk [28] (http://www.umm.uni-heidelberg.de/apps/zmf/mirwalk/index.html).
miRWalk is a comprehensive database that involves not only in silico predicted but also experi-
mentally validated targets. To compare the meta-miRNA targets with meta-mRNAs, common
genes were identified by using Venny [29] (http://bioinfogp.cnb.csic.es/tools/venny/)
In silico analysis of common genes
The independent mRNA microarray data GSE22219 [21] that contains the grade information
was reanalyzed by BRB-ArrayTools [30] to analyze the prediction power of common genes be-
tween validated meta-miRNA targets and meta-mRNAs. Hierarchical clustering of common
genes and tumor samples according to their grade information was performed by using average
linkage as a clustering method.
The interaction network between grade predictive let-7 family members and their potential
target genes validated by in silico analysis of common genes was visualized by using Cytoscape
3.2.0 network analysis and visualization platform [31].
Results
miRNA specific datasets and meta-analysis
In this study to combine independent microarray studies coming from different platforms
ranking-based meta-analysis approach was developed. After evaluation processes we picked 3
miRNAmicroarray studies conducted in breast cancer tumors, which have clinical information
Meta-MicroRNAs in Breast Cancer
PLOS ONE | DOI:10.1371/journal.pone.0126837 May 15, 2015 6 / 16
regarding grade status and available microarray data. Consequently we could apply the meta-
analysis approach to 308 samples from 3 different miRNA microarray studies and 67 samples
were Grade 1, 122 Grade 2 and 119 Grade 3 (Table 1).
The number of probes in each data group was 359 for GSE7842 [19], 396 for GSE15885 [20]
and 735 for GSE22216 [21]. Accordingly the total number of miRNAs included in the study
was 551. The meta-analysis program uses the average values to calculate the real rank of a
miRNA, decreasing the number of miRNAs to 194 at the end of the meta-analysis (S1 Table).
Although the rank of any given miRNA varied from low to high in the individual datasets,
this was stabilized with the real rank at the end of the meta-analysis. In the case of let-7c, the
rank was 11 in GSE7842 [19], 4 in GSE15885 [20] and 12 in GSE22216 [21] according to the
ANOVA results but it took 1st position as its real rank in the meta-list with a mean rank of 9
(Table 2).
Let-7 family members are enriched in meta-miRNA list
As provided in S1 Table, 194 miRNAs were listed according to the mean of their ranks and
they were ordered from 1 to 194 as their real rank scores. Since the real rank in the meta-list
was used instead of the significance value we focused on the first 20 meta-miRNAs listed in
Table 2. The abundance of let-7 family members in the top 20 meta-miRNA list was remark-
able. Eight of the top 20 was found to be consisting of let-7 family members. The first 6 miR-
NAs in the meta-list were let-7c, let-7a, let-7f, let-7d, let-7e, let-7i and let-7g was the 8thand let-
7b was the 11th miRNAs (Table 2). Additionally hsa-miR-7, hsa-miR-99a, hsa-miR-320, hsa-
Table 2. Top 20meta-miRNAs and their ranking values.





















The mean rank indicates the average of rank values in each study for a given miRNA and the real rank is
the rank of a given miRNA in the meta-list generated by the meta-analysis approach.
* indicates the let-7 family members in the meta-list that were chosen for further analysis.
doi:10.1371/journal.pone.0126837.t002
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miR-30a-3p and hsa-miR-30a-5p that were previously associated with breast cancer were also
in the meta-list [32–37]. The amount of cancer related miRNAs in the first top 20 meta-list
might be the indication of the robustness of the miRNAs reliability of them to be real
grade predictors.
Let-7 family targets are associated with cancer specific pathways
To further characterize the relation of let-7 family members with the grade status of breast tu-
mors, the validated targets of the 8 grade-specific meta-miRNAs were identified by miRwalk
[28]. Among all 8 let-7 family members let-7b was found to have the highest number of defined
targets with 663 target genes and let-7i was found to have 269 validated target genes, which was
the lowest target number. On the other hand the number of targets was 299 for hsa-let-7c, 308
for hsa-let-7a, 283 for hsa-let-7f and hsa-let-7d, 301 for hsa-let-7e and 273 targets for hsa-let-
7g.
The target gene lists that were obtained for each miRNA were used for pathway enrichment
analysis that was performed by WebGestalt [24]. The KEGG pathway enrichment results of the
validated target genes were extracted and visualized by a heatmap, which was generated by
using FDR corrected p values of enrichment analysis. The results showed that most of the tar-
get genes were taking part in cancer-related pathways such as the cell cycle, apoptosis and sig-
naling pathways including MAPK, p53, ErbB, Wnt, Jak-STAT and TGF-beta (Fig 2;
p<0.0091). It was also interesting to mention that none of the targets of miRNAs missed any
given pathway and all of them shared each and every pathway given in Fig 2 within a range of
significance between 10–3 and 10–59.
qRT-PCR experiments validated the grade predictive ability of meta-
miRNAs in independent tumor samples
Expression profiles of the eight let-7 family members were tested in independent breast tumors
to validate meta-analysis results by qRT-PCR (n = 21). The expression range of each miRNA
in each grade (Grade1, Grade 2 and Grade 3) was shown in terms of normalized Ct values ac-
cording to a normalization factor RNU6 as box-whisker-plots in Fig 3. Concordant with the
meta-analysis results the expression levels of all let-7 family members were found to be consis-
tently downregulated with increasing tumor grade. Let-7d, let-7i and let7g were observed to be
similar in terms of expression profiles throughout the tumor samples representing each tumor
grade. Since a very wide range of distribution in the expression values of most of the miRNAs
in Grade 2 tumor samples were observed, none of the let-7 family members were found to be
discriminative between Grade 1 and 2 and Grade 2 and 3 tumors. On the other hand the
changes in the expression levels of hsa-let-7a, hsa-let-7c, hsa-let-7e in Grade 1 and Grade 3 tu-
mors were found to be statistically significant (p0.05) (Fig 3).
In silico integrated analysis of meta-miRNA-targets and meta-mRNAs
resulted common mRNAs specific to grade status
To validate the reliability of let-7 family members in grade status discrimination, an integrated
analysis was designed in which the targets of the let-7 family members were compared with the
meta-mRNAs that are supposed to be grade predictors. For this integrated analysis the meta-
analysis approach that was applied to miRNA datasets was also applied to the 2 mRNA micro-
array studies conducted in breast cancer (Table 1) and meta-mRNAs that could classify breast
cancer tumors according to their grade status were ranked. What we expected was to find out
common genes between grade specific miRNA-targets and grade specific meta-mRNAs. That
Meta-MicroRNAs in Breast Cancer
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is because if we could find any mRNAs that are discriminative between grade statuses, they had
to share some genes with the targets of grade predictive-miRNAs.
The intersection of meta-mRNAs (top 20% of 13355 mRNAs) and let-7-target genes (837
targets without repetition) was found by Venny analysis and the results showed that they
shared 116 common genes (Fig 4A, S2 Table). The pathway enrichment analysis results showed
that most of the genes common to meta-miRNA targets and meta-mRNAs took part in impor-
tant pathways such as cancer specific pathways, the cell cycle, TGF-beta signaling pathway, ap-
optosis, MAPK, mTOR and VEGF signaling pathways (p 0.0205).
To further validate the prediction power of the 116 common genes an independent microar-
ray data from GSE22219 [21] were reanalyzed and expression results were visualized by a heat-
map. Primary breast tumors were hierarchically clustered into two major groups based on
target gene expression profiles. This in silico validation showed that 41 of the 116 genes were
able to significantly cluster Grade 1 and Grade 3 tumors. Grade 1 tumors were significantly lo-
cated in the first group (GR1) while the samples in the second group (GR2) were mostly Grade
3 tumors (Fig 4B; Mann-Whitney; W = 1642, p = 0.0000). As expected, some of the target
mRNA expression levels were observed to be increased with increasing grade status, unlike the
miRNA expression levels. The genes that were upregulated in grade 3 tumors may be thought
to be the direct targets of let-7 family members because of their inverse correlation and include
ME1, TXNRD1, POLR2C, SOAT1, PRDM1, SOCS1, TCF19, STMN1, SRM, RDH10, PSAT1,
POLA2, MCM2, LMNB2, TRIP13, IQGAP3, TYMS, SLC7A5, SQSTM1, HMOX1, SLC16A3,
Fig 3. Boxplot of let-7 family expression levels. A consistent decrease in the expression levels of let-7 family members is observed from grade 1 to grade
3 tumors (n = 21).
doi:10.1371/journal.pone.0126837.g003
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SLC25A13, SEC24A, SAMSN1, LAMP3 and SELL (Fig 4B). To visualize the interactions of
each gene with the miRNAs cytoscape network analysis and visualization platform was used.
The network analysis indicated that half of the 26 potential target genes were unique to let-7b
Fig 4. In silico analysis of the common genes between validatedmeta-miRNA targets andmeta-
mRNAs. (A) The intersection of meta-mRNAs and let-7-target genes. 116 of the meta-miRNA targets are in
common with the meta-mRNAs. (B) Heatmap of the expression of common genes between grade-specific let
7 targets and mRNAs for the GSE22219 dataset. Hierarchical clustering of common genes and grade 1 and
grade 3 tumor samples was performed by using average linkage as the clustering method. Red and green
colors represent upregulation and downregulation, respectively (p0.05). (C) The interaction network
between grade predictive let-7 family members and their potential target genes validated by in silico analysis.
Target genes are represented by yellow and circular nodes while miRNAs are represented by squares.
doi:10.1371/journal.pone.0126837.g004
Meta-MicroRNAs in Breast Cancer
PLOS ONE | DOI:10.1371/journal.pone.0126837 May 15, 2015 10 / 16
and this miRNA shared 8 targets with the other let-7 family members. Additionally PRDM1,
SOCS1, TCF19, SRM, SLC7A5 and LAMP were located as the genes targeted by all of the grade
predictive let-7 family members (Fig 4C). The KEGG pathway analysis results indicated that
among 26 genes some of them were found to have roles in cancer related pathways like cell
cycle (MCM2), Jak-STAT (SOCS1), MAPK (STMN1), PPAR signaling pathways (ME1).
Discussion
Meta-analysis is a procedure for statistically combining the results of many different studies.
The data obtained by meta-analysis is more generalized and stable since the information is not
specific to a case but the combination of many different studies. The common problem of vari-
ous meta-analysis approaches is the technical differences resulting from the usage of different
platforms. This necessitates the development of new methodologies with the potential to elimi-
nate the differences resulting from the different probe design, normalization and preprocessing
methods specific to each platform. We combined independent miRNA microarray datasets to
identify miRNA signatures that could classify the breast cancer samples according to their his-
tological grade in this study. An ANOVA-dependent ranking-based meta-analysis approach
that makes identification of novel candidate miRNAs possible with the potential to eliminate
differences emerging from microarray platform variability was developed in MATLAB for this
purpose. The code is so dynamic that it allows the addition of newly generated data for meta-
analysis. In a ranking-based meta-analysis study, Phan et al. compared their Rank Average
Meta-Analysis with 5 other meta-analysis approaches (mDEDs, rank products, Choi, Wang
and naive methods) and found that combining microarray datasets by averaging ranks effec-
tively increases the sample size while enabling robust analysis of heterogeneous data.[18] An-
other ranking-based methodology was proposed by Kolde et al. as a novel rank aggregation
method that is free and robust as regards outliers, noise and errors [38]. Ranking-based algo-
rithms are therefore suggested to be useful and general solutions for the integration of
variable datasets.
The method enabled us to combine three independent miRNA microarray studies per-
formed with three different platforms and two different mRNA microarray studies performed
with the same platform. Since miRNA microarray studies are mostly concentrated on the com-
parison of tumor and normal tissues, the pathological information (including the grade infor-
mation) was not available, which limited the number of studies we used for meta-analysis.
The meta-analysis study was performed with the tumor samples obtained from independent
studies in which the clinical information of the tumors was available. In this study we concen-
trated on meta-miRNAs that are predictive for histological grade status, one of the important
prognostic factors in breast cancer. In the meta-miRNA list obtained from the meta-analysis, 8
of the first 20 miRNAs were found to be let-7 family members; let-7c, let-7a, let-7f, let-7d, let-
7e, let-7i, let-7g and let-7b (Table 2). The enrichment of let-7 family members in the meta-list
led us to focus on the let-7 family and to further investigate their role in grade prediction. We
started with the experimental confirmation of in silico predictions by qRT-PCR. The results of
the qRT-PCR performed with independent breast cancer samples pointed out that the afore-
mentioned eight let-7 family members were differentially expressed between grade 1 and grade
3 tumors and decreased miRNA expression levels were observed with increasing tumor grade.
Among these miRNAs, the decrease in the expression of let-7a, let-7c and let-7e was found to
be statistically significant (Fig 3; n = 21, p0.05). Similar to our results, in a study of Blenkiron
et al., decreased expression levels of these three miRNAs with increasing tumor grade was
shown in a heatmap. Although their focus was not specifically grade status and any let-7 family
expression profiles they gave a list of miRNAs differentially expressed among tumor grades
Meta-MicroRNAs in Breast Cancer
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and the data was extracted from a heatmap that was given in the paper [19]. Grading shows the
differentiation status of the tumors. Grade 1 tumor cells appear close to normal and are differ-
entiated while Grade 3 tumors are poorly differentiated. What we observed in the qRT-PCR ex-
periments was a consistent decrease in the expression levels of miRNAs from differentiated to
poorly differentiated tumors (Fig 3). These findings were supported by a study in which general
miRNA expression levels and differentiation status of the tumors were found to be inversely
correlated [39]. These findings were also consistent with the report that mouse embryonic
stem cells lacking Dicer, an important enzyme for miRNA maturation, fail to differentiate nor-
mally [40]. By reanalyzing the let-7 family members of a very recent study (GSE60725), it was
shown that the same family members were downregulated in grade 3 tumors compared to
grade 2 tumors. Better differentiation of the tumors was therefore positively correlated with
higher miRNA expression levels. Rothe et al. reported that hsa-miR-93, hsa-miR-423, hsa-
miR-25, hsa-miR-106b and hsa-miR-345 that are in top 50 in our meta-miRNA list were bio-
marker candidates for grade prediction between grade 1 and grade 3 tumors.[41] In addition to
the let-7 family members, the qRT-PCR results confirmed that miR-30a-3p and miR-30a-5p,
which were listed among the top 20 meta-miRNAs, were significantly discriminative between
Grade 1 and Grade 2 tumors (p<0.01). The expression levels were found to be increased with
increasing grade (data not shown).Our findings and the literature reports emphasizing the
tumor suppressor roles of let-7 family members and their downregulation in breast tumors
compared to normal cells [11,42,43] not only prove that our meta-analysis tool is reliable but
also increase the potential of let-7 family members and other miRNAs listed at the top of the
meta-list as biomarkers for grade prediction. We also explored the miRNAs in meta-miRNA
list associated with the gene expression grade index (GGI), which is believed to reflect and pro-
vide better proliferation and differentiation information than histological grade [44]. The dif-
ferentially expressed miRNAs between GG low and GG high including let-7i, hsa-miR-379,
hsa-miR-423 and hsa-miR-422a matched our meta-miRNA list and this was consistent with
the findings of Rothe et al [41].
Next, we investigated the let-7 family targets in silico in order to further analyze their pre-
dictive potential regarding histological grade. The validated target gene lists were obtained for
each miRNA (let-7c, let-7a, let-7f, let-7d, let-7e, let-7i, let-7g and let-7b). Further characteriza-
tion of the genes was performed by pathway enrichment analysis. The genes were significantly
enriched in pathways important for cancer development and progression such as Jak-STAT,
MAPK, TGF-beta, mTOR signaling pathways, cell cycle and apoptosis (Fig 2). Since miRNAs
destabilize mRNAs or repress translation by binding to the 3’UTRs of their targets, an increase
in the expression level of a target gene is expected when the miRNA expression level decreases
[8]. The decrease in the expression level of the let-7 family through dedifferentiation suggests
the probability of an increase in the expression levels of target genes since one of the proposed
mechanisms for miRNAs is mRNA destabilization. The fact that CEBPA, one of the common
targets of these miRNAs, and the downstream genes E2F, IL6 and MYC have been shown to
block differentiation and lead the cells to dedifferentiation supports this notion [45].
Many studies have shown the relation of miRNAs with the clinical status of breast cancer
and reported their role in breast cancer pathogenesis, development and progression [20,41,46–
49]. On the other hand, there are only a few studies focusing on the integrated analysis of a
miRNA and the mRNA expression status in breast cancer [19,21,48]. In a study published in
2010, Guo et al. suggested the destabilization of target mRNAs (%84) rather than translation-
al inhibition as the predominant reason for reduced protein output, pointing out mRNAs as
main targets of miRNAs [8]. Data obtained from mRNA and protein expression level compari-
sons after introducing or deleting individual miRNAs also suggested mRNA destabilization to
be the result of miRNA-mediated repression [50,51]. These data indicated the potential value
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of comparing meta-miRNA targets with grade-predictive mRNAs. Accordingly, we used the
meta-analysis approach to independent mRNA microarray studies to determine the mRNAs
that are predictive for breast cancer grade status. We expected the targets (mRNAs) of a
miRNA with real predictive potential for grade status to be expressed differentially between
grade 1, 2 and 3 samples. After obtaining the grade predictive meta-mRNAs by combining in-
dependent mRNA studies by our meta-analysis tool, we found 116 genes to be shared between
the validated targets of let-7 family members and grade-predictive meta-mRNAs (Fig 4A, S2
Table). Pathway enrichment analysis was performed with the common 116 genes and most
were found to be enriched in pathways related to cancer, TGF-beta signaling, the cell cycle, ap-
optosis, MAPK, mTOR and VEGF signaling. It is also important to mention that although the
miRNA and mRNA microarray studies were from independent sources, they shared a number
of mRNAs and miRNA targets that were found to be potential biomarkers for tumor grade.
This consistency not only increases the possibility of the robustness of these 116 genes in
tumor grade prediction but also stabilizes the biomarker roles of miRNAs targeting those
mRNAs.
In conclusion, the meta-miRNAs that were obtained by the meta-analysis developed for this
study could be verified experimentally in independent breast tumors and were comparable
with previous studies related to breast cancer. We have demonstrated that the meta-analysis
approach is reliable and robust and also that the let-7 family members of meta-miRNAs may
be alternative and potential biomarkers for grade prediction. Meta-analysis of miRNAmicroar-
ray datasets also has the potential to lead to more comprehensive measures of the existing dif-
ferential miRNA expression data and can therefore provide miRNA and miRNA-target gene
sets with high prognostic value.
Supporting Information
S1 PRISMA Checklist. PRISMA 2009 checklist. The page numbers corresponding to the
items listed in the checklist were filled out according to the meta-analysis study presented.
(DOC)
S1 Table. Meta-miRNA list. miRNAs were noted according to their ranks in the list. For
each miRNA the mean of its rank in all studies was calculated with their p values (the mean of
rank column) and this value became its real rank in the list within the real rank column, which
was used instead of the significance value.
(XLSX)
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